Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates.
Thiam LG. et al, (2024), NPJ Vaccines, 9
Rational structure-guided design of a blood stage malaria vaccine immunogen presenting a single epitope from PfRH5.
Harrison TE. et al, (2024), EMBO Mol Med
Plug and play virus-like particles for the generation of anti-toxin antibodies.
Edge RJ. et al, (2024), Toxicon X, 23
Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5.
Wang LT. et al, (2024), Cell
Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.
King LDW. et al, (2024), Cell Rep Med, 5
Structure-guided design of aPlasmodium vivaxDuffy binding protein-based vaccine immunogen
Barber NM. et al, (2024)
Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.
Mertens JE. et al, (2024), Vaccine, 42, 3621 - 3629
Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex.
Williams BG. et al, (2024), Nat Commun, 15
PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial.
Martinez FJ. et al, (2024), NPJ Vaccines, 9
The PfRCR complex bridges malaria parasite and erythrocyte during invasion.
Farrell B. et al, (2023), Nature
Human monoclonal antibodies inhibit invasion of transgenic Plasmodium knowlesi expressing Plasmodium vivax Duffy binding protein.
Watson QD. et al, (2023), Malar J, 22